Autifony Therapeutics Limited (“Autifony”) is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.
Our clinical-stage, small molecule modulators of the Kv3 family of potassium channels are poised to demonstrate efficacy in Fragile X syndrome and rare myoclonic epilepsy syndromes. We also have preclinical programmes utilising novel Kv3 modulators with potential across a broad range of CNS disorders, including schizophrenia and hearing loss.
We have leveraged our ion channel drug discovery expertise to build a robust early-stage portfolio of programmes with the potential to deliver novel treatments for neurodegenerative disorders as well as a broader range of CNS disorders, including epilepsy and neuropathic pain.
Autifony is a leader in the translation of ion channel biology into promising new pharmaceutical approaches for the treatment of hearing disorders.
Management and team
Our management team are experts in the discovery and development of novel ion channel drugs. Our expertise spans the early validation of ion channel targets through demonstration of human target engagement to proof-of-concept in patients.
We have focused science teams providing medicinal chemistry, molecular and cell biology, and electrophysiology expertise as well as a clinical team who are experienced in designing and leading clinical trials. Our track records highlight our use of non-invasive CNS biomarkers to demonstrate human CNS target engagement, enable patient stratification, and monitoring of treatment effect. The Autifony team also has unique experience of the design and implementation of clinical trials in hearing disorders.
Autifony Therapeutics Limited has its main office and laboratories in Stevenage (UK) and additional laboratories at Autifony SRL in Padova (Italy).
History and investments
Autifony Therapeutics Limited is a private company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large, Chief Executive Officer and Giuseppe Alvaro, Chief Research Office, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery.
Autifony Therapeutics refers to all companies within the Autifony group, comprising Autifony Therapeutics Limited, and Autifony Srl (Italy).